Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

BRG1 (SMARCA4) Status Dictates the Response to EGFR Inhibitors in Wild-Type EGFR Non-Small Cell Lung Cancer

Cancers(2025)10.3390/cancers18010062Source: DataRank Database

BRG1 (SMARCA4) Status Dictates the Response to EGFR Inhibitors in Wild-Type EGFR Non-Small Cell Lung Cancer is a research paper published in Cancers (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: goldTopics (12)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Ranganayaki Muralidharan,Narsireddy Amreddy,Akhil Srivastava ORCID,Meghna Mehta ORCID,Janani Panneerselvam

Live enrichment

PubMed:41514577 PMC:PMC12784900

National Institutes of Health (NIH)/National Cancer Institute

Grant: R01 CA254192

National Institutes of Health (NIH)/National Cancer Institute

Grant: R01 CA282735

National Cancer Institute Cancer Center

Grant: P30CA225520

National Institutes of Health

Grant: 3P30CA225520-06S4

Stephenson Cancer Center - Cancer Center Support Grant

National Institutes of Health

Grant: 5R01CA282735-02

Engineered Nanoformulation for Immune-modulation in Cancer

National Institutes of Health

Grant: 5R01CA254192-04

Exosomes as carriers of cancer therapeutics

goldLicense: cc-by

publisherhttps://www.mdpi.com/2072-6694/18/1/62/pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12784900/

Europe_PMChttps://europepmc.org/articles/PMC12784900

Europe_PMChttps://europepmc.org/articles/PMC12784900?pdf=render

https://doi.org/10.3390/cancers18010062

Fields of Study

MedicineBiology03 medical and health sciences0302 clinical medicine

Keywords

ResistanceEGFRLung cancerTherapyTyrosine kinase inhibitorBrg1Smarca4Article